Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine

OVX836 is a recombinant protein-based vaccine targeting the highly conserved influenza nucleoprotein (NP), which aims to confer a broad-spectrum protection against influenza. In a Phase 1 study, OVX836, administered intramuscularly, has been found safe and immunogenic. The 90µg and 180µg dose levels...

Full description

Bibliographic Details
Main Authors: Isabel Leroux-Roels, Gwenn Waerlop, Jessika Tourneur, Fien De Boever, Catherine Maes, Jacques Bruhwyler, Delphine Guyon-Gellin, Philippe Moris, Judith Del Campo, Paul Willems, Geert Leroux-Roels, Alexandre Le Vert, Florence Nicolas
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Immunology
Subjects:
influenza
universal vaccine
nucleoprotein
subunit
OVX836
Influvac Tetra
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.852904/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.852904/full

Similar Items